Cardio Diagnostics Launches Epi+Gen CHD™, A New Heart Disease Risk Assessment Test
Retrieved on:
Thursday, January 28, 2021
Diabetes, Pharmaceutical, General Health, Medical devices, Women, Genetics, Fitness & Nutrition, Cardiology, Family, Science, Biotechnology, Consumer, Health, Research, Medical Supplies, Circulatory system, Anatomy, Cardiovascular system, Aging-associated diseases, Heart, Cardiovascular diseases, Framingham Risk Score, Coronary artery disease, Cardiovascular disease, Myocardial infarction, Cardio, Cardio Diagnostics, Inc., InTeleLabs, Inc., MOgene, LC
Primary care clinicians currently have only two tools: the Framingham Risk Score (FRS), and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator, for predicting future heart disease.
Key Points:
- Primary care clinicians currently have only two tools: the Framingham Risk Score (FRS), and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator, for predicting future heart disease.
- Cardio Diagnostics flagship product focuses on risk for coronary heart disease because it is the most common type of heart disease, and the major cause of heart attacks.
- Cardio Diagnostics Chief Executive Officer and Co-Founder, Meeshanthini (Meesha) Dogan Ph.D., shared we are incredibly excited about getting this early risk assessment test to the market.
- Developed in partnership with a team of dedicated scientists and clinicians, the Cardio Diagnostics Epi+Gen CHD test helps clinicians better assess each patients unique risk profile for disease.